Year: 2025
SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) — Endeavor Bancorp (OTCQX: EDVR) (the “Company” or “Bancorp”), the holding company for Endeavor Bank (the “Bank”), today reported net income of $1.07 million, or $0.25 per diluted share, for the second quarter of 2025, compared to $1.36 million, or $0.32 per diluted share, for the first quarter of 2025, and $760,000, or $0.18 per diluted share, for the second quarter of 2024. All financial results are unaudited.
“Our second quarter results reflect the strength of our core banking franchise and the disciplined execution of our strategic growth plan,” said Julie Glance, CFO. “We continued to grow loans and deposits during the quarter while maintaining a strong net interest margin, demonstrating the resilience of our business model in an uncertain interest rate environment. Our strategic investments...
Greene County Bancorp, Inc. Reports Record High Net Income of $31.1 Million for the Fiscal Year Ended June 30, 2025, Announces Plans to Expand into Saratoga County
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
CATSKILL, N.Y., July 23, 2025 (GLOBE NEWSWIRE) — Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for the Bank of Greene County and its subsidiary Greene County Commercial Bank, today reported net income for the quarter and fiscal year ended June 30, 2025. Net income for the quarter and fiscal year ended June 30, 2025 was $9.3 million, or $0.55 per basic and diluted share, and $31.1 million, or $1.83 per basic and diluted share, respectively, as compared to $6.7 million, or $0.40 per basic and diluted share, and $24.8 million, or $1.45 per basic and diluted share, for the quarter and fiscal year ended June 30, 2024, respectively. Net income increased $2.6 million, or 38.6%, when comparing the quarters ended June 30, 2025 and 2024, and increased $6.3 million, or 25.7%, when comparing the fiscal years...
Philips advances minimally invasive therapy procedures in prostate cancer care with FDA 510(k) clearance for image-guided navigation technology
Written by Customer Service on . Posted in Public Companies.
DynaCAD urology with advanced annotationUroNav cart with advanced annotation optionUroNav with advanced annotationJuly 23, 2025
Supporting prostate cancer diagnosis with more precise guidance for clinicians, offering better patient care
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advancement in image-guided navigation for prostate cancer care with the FDA 510(k) clearance of the latest Philips UroNav version. The system includes a new advanced annotation [1] workflow that supports clinicians during focal therapy procedures, helping deliver more precise, minimally invasive care.
This release comes at a time of increasing need for innovation in prostate cancer care. Prostate cancer remains the most commonly diagnosed solid tumor...
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
Written by Customer Service on . Posted in Public Companies.
Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial evaluating CMND-100, a proprietary oral drug candidate for Alcohol Use Disorder (AUD). This milestone advances Clearmind’s mission to transform treatment for the global epidemic of AUD, which affects millions and accounts for 2.6 million deaths annually.
The Phase I/IIa trial, already underway at prestigious sites, including Yale School of Medicine and Johns Hopkins University in the United...
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
Written by Customer Service on . Posted in Public Companies.
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body
Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target
Emerging new preclinical data on impact of PH1 payload against a key oncogenic driver is expected before year-end
BOSTON and LONDON, July 23, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today reiterated its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator, PH1, having demonstrated it may also act to inhibit key drivers in cancer tumors.
“We are excited to build on the scientific data already established...
Dave to Host Second Quarter 2025 Conference Call on August 6, 2025 at 8:30 a.m. ET
Written by Customer Service on . Posted in Public Companies.
LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) — Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE), one of the nation’s leading neobanks, will host a conference call on Wednesday, August 6, 2025 at 8:30 a.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2025. The Company’s results will be reported in a press release on the same day, prior to the conference call.
Dave management will host the conference call, followed by a question-and-answer period. The conference call details are as follows:
Date: Wednesday, August 6, 2025Time: 8:30 a.m. Eastern timeToll-free dial-in number: (866) 652-5200International dial-in number: (412) 317-6060Webcast: link
The conference call will also be available for replay in the Events section of the Company’s website, along with the transcript, at https://investors.dave.com.
If...
Hudson RPO Acquires Alpha Consulting Group (ACG) Japan
Written by Customer Service on . Posted in Mergers And Acquisitions.
Acquisition Marks Entrance into Japan, Enhancing Hudson RPO’s Already Strong Leadership Position in the APAC Region
OLD GREENWICH, Conn., July 23, 2025 (GLOBE NEWSWIRE) — Hudson Global, Inc. (the “Company” or “Hudson RPO”) (Nasdaq: HSON), a leading global total talent solutions company, announced today the acquisition of Alpha Consulting Group (“ACG”), a Japan-based (Tokyo) provider of recruitment services to a variety of companies, ranging from small- and medium-sized businesses to blue-chip and multinational organizations primarily in the IT Services, Technology, and Business Services sectors. Entrance into the Japanese market represents a localization strategy for Hudson RPO in the 2nd largest market within APAC and the 3rd largest market globally.
Jake Zabkowicz, Global CEO of Hudson RPO, noted, “Today’s announcement fits well...
IperionX – June 2025 Quarterly Report
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
CHARLOTTE, N.C., July 23, 2025 (GLOBE NEWSWIRE) — IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) is pleased to present its quarterly report for the period ending June 30, 2025. Key highlights during and subsequent to the end of the quarter include:
Commercial operations: production online and commissioning of all major equipment completeSuccessful commissioning of the Titanium Manufacturing Campus in Virginia, with all major scrap-to-forged titanium manufacturing equipment now online and proven to meet operational capacity.
Repeated back-to-back production cycles of the Hydrogen Assisted Metallothermic Reduction (HAMRTM) furnace continue to produce high-quality titanium that exceeds industry standards.
Commissioning-phase process improvements have reinforced the low-capex modular scalability of the HAMR process and underscore...
Matador Technologies Inc. Secures USD $100 Million Financing Facility to Accelerate Bitcoin Treasury Growth
Written by Customer Service on . Posted in Public Companies.
Key HighlightsStrategic Capitalization: Matador has executed a Purchase Agreement for a USD $100 million secured convertible note facility (the “Facility”) with ATW Partners, featuring an initial USD $10.5 million tranche.Exclusive Use of Proceeds: Proceeds are earmarked for purchasing Bitcoin as part of Matador’s treasury allocation strategy, with the intention of increasing long-term Bitcoin-per-share (BPS).Institutional Partnership: ATW Partners—an institutional investor known for structuring growth-stage financings—brings both capital and strategic depth to Matador’s Bitcoin ecosystem vision.
Flexible, Equity-Aligned Structure: The secured convertible notes provide minimally dilutive, price-adaptive funding that converts at market-aligned prices.Accelerates Treasury Plan: Supports Matador’s roadmap to acquire up to 1,000 BTC...
Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Written by Customer Service on . Posted in Public Companies.
Video webcast now available on-demand
MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc., today announced that John Erb, President and Chief Executive Officer of Nuwellis, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference.
For the event, Mr. Erb dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s programs in development.
The on-demand video webcast is now available on the www.virtualinvestorco.com as well as the Newsroom page under the Investors section of the Company’s website (www.nuwellis.com).
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and...